TP63 and fungal infectious disease: Although they are not currently used to treat invasive mold mycoses, FLC and KET were investigated in these organisms as they have previously demonstrated antifungal synergy with bisphosphonates (15, 16), and because combination therapy could potentially improve the efficacy of FLC and rejuvenate KET for a broader selection of mold pathogens.